ALIPAY+
9.1.2023 07:16:19 CET | Business Wire | Press release
Alipay+, a provider of global cross-border digital payment and marketing solutions, is striving to provide cash-free and mobile-friendly travel experiences for Asian tourists in the Chinese mainland, as it seeks to partner with more merchants and enable greater QR code connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230107005009/en/
AlipayHK users are now able to pay for metro rides in Shenzhen using the app the same way they do at home, as China begins to optimize regulations on travel between mainland and Hong Kong. (Photo: Business Wire)
Starting from January 8, AlipayHK users can pay for metro rides in Shenzhen using their local app to enhance a seamless travel experience for Hong Kong visitors in the mainland. The service is enabled through joint efforts between Alipay+ and the city’s subway operator, following a similar payment system integration with bus operators in major cities across Guangdong province.
Venetia Lee, General Manager of Ant Group Greater China International Business, said, “As a pioneer in the field of digital life, we hope to play a bigger role in building digital infrastructure to enhance connectivity in the Greater Bay Area, and contribute to the better development of the region.”
The expanded acceptance of AlipayHK comes as China begins to optimize regulations on travel between mainland and Hong Kong, lifting quarantine requirements that were in place for almost three years.
“As the demand for travels between mainland and Hong Kong remains strong and cross-bound activities begin to normalize, we expect to witness the wide adoption of AlipayHK on the Chinese mainland, where Alipay+ solutions have already been adopted by millions of merchants that are ready for the return of international travelers,” said Lee.
Powered by Alipay+ solutions, AlipayHK, one of the most popular e-wallets in Hong Kong, is now widely accepted in the mainland by retailers, convenient stores, supermarkets, restaurants, cafes, bubble tea shops, hotels and other tourist spots in the mainland, where users can scan the same local merchant’s QR code for payment or present their in-app QR code to be scanned for payment.
Cash Free Travel to Users of Alipay+ Mobile Payment Partners
The connectivity with merchants across China is not limited to AlipayHK. Last November, Alipay+ announced on the sideline of the Singapore Fintech Festival that its mobile payment partners including South Korea’s Kakao Pay and Malaysia’s Touch 'n Go eWallet would soon be accepted in mainland, in a drive to facilitate payments from international visitors ahead of the Hangzhou Asian Games.
After a trial run in Yiwu, Zhejiang province, users of Kakao Pay and Touch 'n Go eWallet are expected to pay in a seamless way with their respective apps while getting around in Hangzhou and its neighboring cities where the Hangzhou Asian Games will take place, in addition to other major Chinese cities including Beijing, Shanghai and Shenzhen.
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by the merchants through Alipay+.
Alipay+ Global Footprint
Globally, over the past year Alipay+’s merchant coverage has more than doubled since last year to over 2.5 million, which includes regional and global digital entertainment providers, lifestyle services, e-commerce platforms and a wide range of brick-and-mortar businesses that cover major airports, shopping centers, duty free shops, convenience stores, cafes, restaurants and tourism facilities.
Businesses across Japan, South Korea, Singapore, Malaysia and other Southeast Asian markets are embracing Alipay+ to connect with over 15 digital payment methods through one-time integration, and better engage with over 1 billion consumers.
Alipay+’s merchant coverage includes over 1,000 online platforms, more than 10 major airports, over 90,000 convenience stores, over 360,000 restaurants, nearly 200,000 taxis and major hotel brands, department stores, duty-free shops and tourist facilities in Asia and Europe.
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230107005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
